Gamida Cell said today that the 1st patient has been treated in the Phase III registration trial of its NiCord cell graft for patients with blood cancer. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the company.
The Jerusalem-based company’s cell graft was designed as an alternative to bone marrow transplantation for patients with blood cancer who do not have a fully matched donor.
Get the full story at our sister site, Drug Delivery Business News.
The post Gamida Cell touts first patient treated in Phase III NiCord trial appeared first on MassDevice.
from MassDevice http://ift.tt/2lkX1RA
Cap comentari:
Publica un comentari a l'entrada